Literature DB >> 217998

Adenine nucleotides in cholinergic transmission: presynaptic aspects.

M J Dowdall.   

Abstract

1. Isolated nerve terminals (T-sacs and synaptosomes) prepared from the purely cholinergic Torpedo electric organ have been studied for their ability to incorporate and metabolise [2-3H] adenosine and to degrade 5'-AMP to adenosine. 2. A temperature-dependent, saturable uptake system for adenosine was found with kinetic properties similar to nucleoside transport systems in other cells. The uptake system in Torpedo nerve terminals was inhibited by 2'-deoxyadenosine, a known inhibitor of adenosine transport. 3. Intraterminal adenosine is rapidly metabolised to a number of products including AMP, ADP and ATP. 4. Isolated nerve terminals contain considerable 5'-nucleotidase activity, most of which resides on the outer face of the external membrane. The Km of the enzyme is congruent to 5 micron and it is inhibited by a phosphonate analogue of ADP, alpha-beta-methylene-ADP. It is suggested that this 5'-nucleotidase plays an important role in the production of adenosine from a nucleotide pool in the synaptic cleft.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 217998

Source DB:  PubMed          Journal:  J Physiol (Paris)        ISSN: 0021-7948


  3 in total

1.  Adenosine production inside rat polymorphonuclear leucocytes.

Authors:  A C Newby; C A Holmquist
Journal:  Biochem J       Date:  1981-11-15       Impact factor: 3.857

2.  Dual effects of adenosine on acetylcholine release from myenteric motoneurons are mediated by junctional facilitatory A(2A) and extrajunctional inhibitory A(1) receptors.

Authors:  Margarida Duarte-Araújo; Carlos Nascimento; M Alexandrina Timóteo; Teresa Magalhães-Cardoso; Paulo Correia-de-Sá
Journal:  Br J Pharmacol       Date:  2004-03-01       Impact factor: 8.739

Review 3.  The purinergic neurotransmitter revisited: a single substance or multiple players?

Authors:  Violeta N Mutafova-Yambolieva; Leonie Durnin
Journal:  Pharmacol Ther       Date:  2014-06-02       Impact factor: 12.310

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.